NHS England tariff-excluded drugs list

Version: 14.1
Last updated: April 2019

The NHS England drugs list describes those specialised medicines which are not reimbursed through national prices and are commissioned directly through NHS England. The following tables enable you to search by:

  • drug names and indications
  • the relevant technology appraisal or commissioning policy
  • where to look for the criteria for starting and stopping a medication
  • monitoring and audit requirements
  • where a drug is only appropriate for a specialist centre
  • whether a drug is suitable for shared care (e.g. between specialist and secondary care, or with primary care).

Note that:

  • where a drug is marked as ‘Specialist centre only’, this includes outreach when delivered as part of a provider network
  • where a drug is marked as ‘Suitable for shared care with primary care’, this is only if supported by the local prescribing committee.

A list of footnotes can be found at the bottom of this page.

Medicines not reimbursed through national prices and directly commissioned by NHS England

wdt_ID Drug name Indication TA/Policy Starting criteria Stopping criteria Monitoring/audit requirements Specialist centre only? Suitable for shared care between specialist and secondary care? Suitable for shared care with primary care?
1 ABACAVIR HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS AGREED REGIONAL GUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET
2 ABACAVIR + LAMIVUDINE + DOLUTEGRAVIR (TRIUMEQ®) HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS NHS ENGLAND CLINICAL COMMISSIONING POLICY: B06/P/b/AGREED REGIONAL GUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET
3 ABACAVIR + LAMIVUDINE HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET
4 ABALOPARATIDE MALE AND JUVENILE OSTEOPOROSIS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL
5 ABATACEPT JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d; TA 373 NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY
6 ABIRATERONE CANCER TA259, 387 (SEE ALSO SSC1438) ONLY IN ENZALUTAMIDE NAÏVE PATIENTS NICE/NHS ENGLAND POLICY NICE SACT
7 ADALIMUMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d; TA 373 NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY
8 ADALIMUMAB UVEITIS - ADULTS TA460 NICE NICE NICE AUDIT
9 ADALIMUMAB BEHCETS SYNDROME HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA
10 ADALIMUMAB HIDRADENITIS SUPPURATIVA NICE TA 392 NICE NICE NICE AUDIT
Drug name Indication TA/Policy Starting criteria Stopping criteria Monitoring/audit requirements Specialist centre only? Suitable for shared care between specialist and secondary care? Suitable for shared care with primary care?

Other drugs not listed under payment by results (PbR) exclusions

wdt_ID Drug name Indication TA/Policy Starting criteria Stopping criteria Monitoring/audit reuqirements Specialist centre only Suitable for shared care between specialist and secondary care Suitable for shared care with primary care
2 3,4 DIAMINOPYRIDINE LAMBERT EATON MYASTHENIC SYNDROME AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES
3 ALBUMIN BOUND PACLITAXEL CANCER TA 476 NICE NICE SACT
4 ALECTINIB CANCER TA 536 NICE NICE SACT
5 ARSENIC TRIOXIDE CANCER TA 526 NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY STATEMENT 170072P NICE NICE SACT
6 ATEZOLIZUMAB CANCER TA 520 & TA525 CDF (TA 492) NICE CDF NICE CDF SACT
7 AUTOLOGOUS CHONDROCYTE IMPLANTATION ARTICULAR CARTILAGE DEFECT TA 477 & TA 508 NICE NICE NICE AUDIT
8 AVELUMAB CANCER TA 517 CDF NICE CDF NICE CDF SACT
9 AXICABTAGENE CILOLEUCEL CANCER TA 559 CDF CDF SACT
10 AZATHIOPRINE TRANSPLANT IMMUNOSUPPRESSION ONLY NEW PATIENTS ONLY UNTIL FORMAL REPATRIATION AGREED TRUST GUIDELINES TRUST GUIDELINES ✔* ✔*
11 BENDAMUSTINE CANCER TA216 CDF POLICY NHS ENGLAND POLICY (WITH RITUXIMAB) 170055P, 17088P & 170054P NICE CDF NHS ENGLAND POLICY NICE CDF NHS ENGLAND POLICY SACT
Drug name Indication TA/Policy Starting criteria Stopping criteria Monitoring/audit reuqirements Specialist centre only Suitable for shared care between specialist and secondary care Suitable for shared care with primary care

Footnotes

* Drug is being repatriated from primary to secondary care therefore supply route may vary at present

** Routinely commissioned in combination when dual therapy required

*** Only when prescribed in an adult specialist centre

**** Only where it is a recognised multiple sclerosis (MS) centre with specialist nurse support

Additional notes

  1. Where the funded indication is for paediatric use the CCG will become the responsible commissioner when the patient is transferred to the adult service
  2. CCGs are the responsible commissioner for rituximab in adult non-cancerous haematological conditions (e.g. immune thrombocytopaenic purpura) and non-specialist auto-inflammatory conditions (e.g. rheumatoid arthritis)
  3. Eltrombopag and romiplostim are the responsibility of CCGs regardless of the cause of the thrombocytopenia in adults (paediatrics are NHS England responsibility)
  4. It is a mandated requirement that all use of chemotherapy is recorded in the Systemic Anti-Cancer Therapy (SACT) database including those treatments funded through the Cancer Drugs Fund
  5. Use in vascular disease is commissioned by NHS England within specialist centres—CCGs are responsible for all other indications
  6. NHS England is the responsible commissioner when somatropin analogues (growth hormone) are prescribed in specialist centres for indications falling outside NICE guidance
  7. NHS England commissions anti-retrovirals (ARVs) as per published policies, for the treatment of people with diagnosed HIV infection and for those thought to be HIV positive (post-exposure prophylaxis). NHS England does not routinely commission pre-exposure prophylaxis and this is only available to those enrolled in clinical studies or other NHS England agreed schemes
  8. Drugs approved by NICE for adult conditions will be commissioned in children at specialised paediatric centres if the patient meets the NICE criteria and there is evidence to suggest that the drug is safe and clinically appropriate to use in children as per the NHS England medicines for children policy and a BlueTeq form is available. This includes drugs normally commissioned by CCGs in adults e.g. adalimumab, etanercept, infliximab etc. Please note that medicines funded under the NHS England medicines for children policy may have additional criteria with respect to access.

Contains public sector information licensed under the Open Government License v3.0.

The original version of this table can be found on the NHS England website.